Dental Pulp Diseases ; therapy ; Humans ; Root Canal Therapy

Dental Pulp Diseases ; therapy ; Dental Restoration, Permanent ; Dentist-Patient Relations ; Feeding Behavior ; Humans ; Oral Hygiene ; Periodontal Diseases ; therapy ; Tooth Loss

Dental Pulp Diseases ; therapy ; Humans ; Periapical Diseases ; therapy ; Root Canal Obturation

Drugs, Chinese Herbal ; therapeutic use ; Humans ; Medicine, Chinese Traditional ; methods ; Phytotherapy ; methods

Objective:To investigate the methyl-CpG-binding protein 2 (MeCP2) expression in specimens of pancreas cancer tumor and para-cancerous tissues and its prognostic value.Methods:The tissue microarray and immunohistochemistry were used to examine the MeCP2 expression in 59 cases of pancreatic cancer tumor tissues and 53 adjacent normal tissues. The correlation between the MeCP2 expression and clinicopathological characteristics of pancreas cancer patients was analyzed. Furthermore, the survival curve was drawn by Kaplan-Meier method and the Cox regression hazards model was used to study the prognostic value of MeCP2 expression in pancreas cancer.Results:The MeCP2 positive expression rate in 59 pancreas cancer tumor tissues was 47.5%, which was 67.9% in 53 adjacent tissues. The MeCP2 positive expression rate in adjacent tissues was obviously higher than that in pancreatic cancer tissues, and the difference was statistically significant ( P<0.05). The MeCP2 positive expression was significantly associated with pathological grade and lymph node metastasis(both P<0.05). The overall survival in patients positive for the MeCP2 expression was longer than that in those with negative MeCP2 expression( P<0.05). Cox multivariate analysis demonstrated that the level of MeCP2 expression was an independent predictor for prognosis in patients with pancreas cancer. Conclusions:MeCP2 is obviously positively expressed in para-cancerous tissues, but was lowly expressed in pancreatic cancer, indicating that MeCP2 detection can help to evaluate the prognosis of pancreatic cancer patients.

Objective:To explore the clinical significance of the combined detection of Clara cell secretory protein 16 (CC16) and soluble receptor for advanced glycation end product (sRAGE) in the diagnosis and prognosis of acute respiratory distress syndrome (ARDS).Methods:100 ARDS patients admitted to the intensive care unit (ICU) of Chu Hsien-I Memorial Hospital of Tianjin Medical University from July 2019 to September 2020 were enrolled as the ARDS group, and 100 non-ARDS patients admitted to the ICU during the same period were enrolled as the control group. The general information, vital signs, blood gas analysis, serum CC16 and sRAGE levels, duration of mechanical ventilation, length of ICU stay and prognosis during hospitalization were collected. The receiver operating characteristic (ROC) curve was drawn and the area under ROC curve (AUC) was calculated to evaluate the clinical value of CC16 and sRAGE lonely or combination in the diagnosis and prognosis of ARDS.Results:The duration of mechanical ventilation in the ARDS group was significantly longer than that in the non-ARDS group (days: 15.44±3.04 vs. 12.61±3.73, P < 0.01), and the hospitalization mortality was higher (38.0% vs. 9.0%, P < 0.01), but there was no significant difference in gender, age, body mass index (BMI), acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score or the length of ICU stay between the two groups. There were 62 ARDS patients survived and 38 ARDS patients died during hospitalization. The APACHEⅡ score of the death group was significantly higher than that of the survival group (23.55±2.83 vs. 19.40±4.10, P < 0.01), but there was no significant difference in age, BMI, oxygenation index, mean arterial pressure, duration of mechanical ventilation or the length of ICU stay between the two groups. The serum levels of CC16 and sRAGE in the ARDS group were significantly higher than those in the non-ARDS group [CC16 (mg/L): 38.78±14.70 vs. 21.87±2.45, sRAGE (pg/L): 2 470.95±288.70 vs. 2 013.22±131.15, both P < 0.01]; and the serum levels of CC16 and sRAGE of ARDS patients in the death group were significantly higher than those in the survival group [CC16 (mg/L): 42.02±10.81 vs. 30.52±9.47, sRAGE (pg/L): 2 638.34±324.07 vs. 2 279.91±163.70, both P < 0.01]. ROC curve showed that the AUC of CC16 and sRAGE in the diagnosis of ARDS alone were 0.859 [95% confidence interval (95% CI) was 0.808-0.911] and 0.821 (95% CI was 0.762-0.879), and the best cut-off values were 25.76 mg/L and 2 203.00 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.932 (95% CI was 0.900-0.965) with the sensitivity of 89.0% and the specificity of 87.6%. The AUC of CC16 and sRAGE in predicting the death of patients with ARDS during hospitalization were 0.747 (95% CI was 0.651-0.843) and 0.819 (95% CI was 0.737-0.902), and the best cut-off values were 32.95 mg/L and 2 554.50 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.900 (95% CI was 0.828-0.972) with the sensitivity of 88.7% and the specificity of 84.5%. Conclusions:Serum CC16 and sRAGE have clinical value for the diagnosis and prognosis of ARDS. The combined detection of them is superior to individual detection for early prediction of ARDS and prognosis.

OBJECTIVE:To discuss the contradictions existing during the time when a drugstore pharmacist is doing his duty.METHOD:The existing contradictions were analyzed.RESULTS&CONCLUSIONS:Pharmacists should be educated to solve the contradictions and strengthen propaganda;The evaluating system should be strictly enforced,and the registered pharmacists should be strictly evaluated;Surveillance should be strengthened and the regular supervising system should be established.

Vaccine is expected to be a promising tool for malaria prevention and control.However, safe and effe-ctive malaria vaccine is not yet available for field use so far.They can be pre-erythrocytic stage vaccine, blood stage vac-cine and transmission-blocking vaccine.This review summarizes the progress of the vaccine development in the recent field trials.

Objective To investigate the flora of pathogens and antibiotic resistance of urinary tract infection after spinal cord injury. Methods From June, 2014 to June, 2015, 145 inpatients with urinary tract infection after spinal cord injury were reviewed. Results The main pathogenic germs were found as E. coli (48.9%), K. pneumonia (19.7%) and P. mirabilis (9.0%), and they were resistant to the second or third generation cephalosporins and quinolones moderately or severely, but sensitive toβ-lactamase inhibitor combinations and aminogly-cosides. The strategy of antibiotics need more reasonable. Conclusion The main pathogens in urinary tract infection after spinal cord injury are Gram-negative bacilli, that are resistant to antibiotics. The antibiotics should be selected and used rationally according to bacterial culture.

Objective To investigate the distribution and drug resistance of pathogen for pulmonary infection in cervical spinal cord inju-ry (CSCI) patients, and analyze the application of antibiotics. Methods From January, 2014 to June, 2015, 156 patients with CSCI were re-viewed. The bacteriology and drug resistance were investigated, as well as the application of antibiotics. Results There were 45 cases with nosocomial infection of 68 times, and 106 strains of bacteria in total. The top four Gram-negative pathogens were Klebsiella pneumonia (17.9%), Pseudomonas aeruginosae (15.1%), Encherichia coli (11.3%) and Acinetobacter baumannii (8.5%). The main Gram-positive cocci was Staphylococcus aureus (9.4%), and the main fungi was Candida tropicalis (0.7%). Gram-negative bacteria was resistant to the second or third generation cephalosporins and quinolones moderately or severely, but sensitive toβ-lactamase inhibitor combinations and aminoglyco-sides. The main Gram-positive cocci were sensitive to vancomycin. The application of antibiotics needed to be improved. Conclusion The Gram-negative bacteria are the chief pathogen for pulmonary infection in CSCI patients, which show multiple drug-resistant. It is significant to monitor the drug resistance of bacteria and optimize antibiotics.